Clinical Trial Update: Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating nivolumab alone or with azacitidine in patients with recurrent, resectable osteosarcoma. The study is currently active but not…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteosarcoma
• Sarcoma

Drugs mentioned

• VIDAZA (AZACITIDINE)
• nivolumab (nivolumab)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Osteosarcoma, Osteosarcoma in Children | Phase 1 | Status: ACTIVE_NOT_RECRUITING